Ziltivekimab for myocardial infarction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Dec 2025: Trial started, NCT07301034
  2. 24 Dec 2025: Trial registered, NCT07301034

The trials

NCT07301034: A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

State
Under way
Phase
Phase 3
People
332 planned
Started
18 Dec 2025
Primary completion
14 Nov 2028
Arms
Ziltivekimab dose level 1 + standard of care (SOC)
Results
None posted
  1. 18 Dec 2025: Trial started
  2. 24 Dec 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Ziltivekimab B, Ziltivekimab C.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.